FUJIFILM DEBUTS ASPIRE BELLUS II, A NEW MULTIMODALITY MAMMOGRAPHY WORKSTATION
The latest workstation will be on display this spring at the National Consortium of Breast Centers (NCoBC) conference and the Society of Breast Imaging (SBI) Symposium.
STAMFORD, Conn., March 7, 2018 – FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging products with a comprehensive portfolio of women’s health solutions, will unveil its latest mammography diagnostic workstation, the ASPIRE Bellus II, at the National Consortium of Breast Centers (NCoBC) conference (booth #809) on March 9 -14, 2018 in Las Vegas and the Society of Breast Imaging (SBI) Symposium (booth #332) on April 12 -15, 2018 in Las Vegas.
“With early detection as the leading defense against breast cancer it is crucial that radiologists are armed with the right technology to inform diagnoses,” said Rob Fabrizio, Director of Strategic Marketing, Digital Radiography and Women’s Health, FUJIFILM Medical Systems U.S.A., Inc. “The ASPIRE Bellus II, a one-stop workstation solution designed specifically for mammographic diagnosis, aims to streamline workflow and optimize image displays enabling radiologists to make a more precise diagnosis.”
The ASPIRE Bellus II smart mammography workstation offers a multimodality view for radiologists in an exceptional hi-resolution display and also offers 2D and tomosynthesis comparisons. While supporting a range of DICOM formats, the system is designed around the unique requirements of mammography. The ASPIRE Bellus II incorporates key diagnostic features such as current and prior image comparison, quadrant view, tomosynthesis support and invert. To optimize workflow the ASPIRE Bellus II enables customization for reading protocols and personalized configuration. It received 510(k) clearance from the United States Food and Drug Administration in September 2017 and will begin shipping to customers in spring 2018.
At both conferences, Fujifilm will also exhibit the ASPIRE Cristalle digital mammography system with digital breast tomosynthesis (DBT) option. It combines state-of-the-art, Hexagonal Close Pattern (HCP) image capture technology and intelligent image processing, optimizing both contrast and dose based on auto recognition of breast characteristics. This advanced technology is designed to optimize image acquisition, regardless of breast composition and at a low dose. In addition, the ASPIRE Cristalle helps deliver noticeable patient comfort with its patented, flexible Comfort Paddle intended to provide gentle, even compression of the breast.
Visit Fujifilm at NCoBC at booth #809.
Visit Fujifilm at SBI booth #332.
FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From an unrivaled selection of digital X-ray systems, to the Synapse® brand of PACS, RIS and cardiovascular products, to advanced women’s health imaging systems, Fujifilm has products that are ideal for any size imaging environment. The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. supplies high quality, technologically advanced FUJINON brand endoscopes to the medical market. TeraMedica Division delivers healthcare informatics, and is the leading provider of vendor neutral, enterprise-wide solutions for unrestricted medical image management. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Stamford, CT. For more information please visit www.fujimed.com and www.fujifilmendoscopy.com.
FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2017, the company had global revenues of $20.7 billion, at an exchange rate of 112 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.
All product and company names herein may be trademarks of their registered owners.